{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:07:52Z","timestamp":1788847672084,"version":"build-2803163510"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Despite extensive research on SARS-CoV-2 immunity, longitudinal studies integrating functional neutralization, antigenic relationships, and host genetic variability remain limited, particularly in Southeast Asian populations with distinct HLA backgrounds. Here, we performed a longitudinal analysis of a Vietnamese COVID-19 cohort before and after vaccination to characterize determinants of cross-variant antibody responses. Our findings indicate that while HLA polymorphisms contribute to inter-individual variability following natural infection, vaccination substantially enhanced cross-variant neutralization and reduced the apparent contribution of HLA-associated variability of neutralizing responses across genetically diverse individuals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We analyzed 189 Vietnamese COVID-19 convalescent individuals at approximately 7 months post-infection (unvaccinated) and 72 individuals at approximately 15 months (predominantly vaccinated). Anti-S1 and anti-RBD IgG were quantified by ELISA, and neutralizing antibody titers (PRNT\n                      <jats:sub>50<\/jats:sub>\n                      ) were measured against Wuhan and major variants of concern. High-resolution HLA genotyping was performed using next-generation sequencing, and associations with antibody responses were evaluated using linear regression models with correction for multiple comparisons.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Vaccination markedly increased antibody levels and neutralizing titers across all variants, with fold-increases ranging from approximately 10-fold (Omicron) to 132-fold (Wuhan). Neutralization breadth expanded substantially after vaccination, although reduced activity against Omicron persisted. Strong correlations between binding and neutralizing antibodies were observed, particularly post-vaccination. While several HLA alleles were associated with variation in neutralizing antibody magnitude at earlier time points, multivariable analyses demonstrated that vaccination was the strongest factor associated with neutralization breadth at 15 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Vaccination robustly enhances both the magnitude and breadth of humoral immunity in previously infected individuals, consistent with hybrid immunity. Although HLA polymorphisms contribute to inter-individual variability, their contribution appeared smaller than the effect associated with vaccination. These findings highlight how vaccination reshapes immune variability across genetically diverse populations and provide population-specific insight into long-term SARS-CoV-2 immunity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1865246","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:35:47Z","timestamp":1788845747000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal analysis of hybrid immunity in a Vietnamese COVID-19 cohort demonstrates vaccination-associated broadening of cross-variant neutralization across diverse HLA backgrounds"],"prefix":"10.3389","volume":"17","author":[{"given":"Thi Thanh Ngan","family":"Nguyen","sequence":"first","affiliation":[{"name":"Graduate School of Biomedical Sciences, Nagasaki University","place":["Nagasaki, Japan"]},{"name":"Department of Virology, Institute of Tropical Medicine, Nagasaki University","place":["Nagasaki, Japan"]},{"name":"National Institute of Hygiene and Epidemiology","place":["Hanoi, Vietnam"]},{"name":"Dejima Infectious Disease Research Alliance (DIDA), Nagasaki University","place":["Nagasaki, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim Mai","family":"Huynh","sequence":"additional","affiliation":[{"name":"Pasteur Institute of Nha Trang","place":["Nha Trang, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hien Anh Thi","family":"Nguyen","sequence":"additional","affiliation":[{"name":"National Institute of Hygiene and Epidemiology","place":["Hanoi, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung Thai","family":"Do","sequence":"additional","affiliation":[{"name":"Pasteur Institute of Nha Trang","place":["Nha Trang, Vietnam"]},{"name":"Department of Pediatric Infectious Diseases, Institute of Tropical Medicine, Nagasaki University","place":["Nagasaki, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouichi","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Virology, Institute of Tropical Medicine, Nagasaki University","place":["Nagasaki, Japan"]},{"name":"Dejima Infectious Disease Research Alliance (DIDA), Nagasaki University","place":["Nagasaki, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Futoshi","family":"Hasebe","sequence":"additional","affiliation":[{"name":"Graduate School of Biomedical Sciences, Nagasaki University","place":["Nagasaki, Japan"]},{"name":"Dejima Infectious Disease Research Alliance (DIDA), Nagasaki University","place":["Nagasaki, Japan"]},{"name":"Vietnam Research Station, Center for Infectious Disease Researcher in Asia and Africa, Institute of Tropical Medicine, Nagasaki University","place":["Nagasaki, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Quynh Mai","family":"Le","sequence":"additional","affiliation":[{"name":"National Institute of Hygiene and Epidemiology","place":["Hanoi, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Shiina","sequence":"additional","affiliation":[{"name":"Department of Molecular Life Sciences, Tokai University School of Medicine","place":["Kanagawa, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lay-Myint","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Graduate School of Biomedical Sciences, Nagasaki University","place":["Nagasaki, Japan"]},{"name":"Department of Pediatric Infectious Diseases, Institute of Tropical Medicine, Nagasaki University","place":["Nagasaki, Japan"]},{"name":"Vietnam Research Station, Center for Infectious Disease Researcher in Asia and Africa, Institute of Tropical Medicine, Nagasaki University","place":["Nagasaki, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng Ling","family":"Moi","sequence":"additional","affiliation":[{"name":"Graduate School of Biomedical Sciences, Nagasaki University","place":["Nagasaki, Japan"]},{"name":"School of International Health, Graduate School of Medicine, The University of Tokyo","place":["Tokyo, Japan"]},{"name":"The University of Tokyo Pandemic Preparedness (UTOPIA), Infection and Advanced Research Center","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.12839","article-title":"Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review","volume":"324","author":"Wiersinga","year":"2020","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjid.2021.101606","article-title":"The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines","volume":"25","author":"Mohammadi","year":"2021","journal-title":"Braz J Infect Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04266-9","article-title":"Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation","volume":"602","author":"Saito","year":"2022","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110829","article-title":"Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant","volume":"39","author":"Liu","year":"2022","journal-title":"Cell Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1126\/science.abq1841","article-title":"Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure","volume":"377","author":"Reynolds","year":"2022","journal-title":"Science"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00365-6","article-title":"Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies","volume":"22","author":"Yamasoba","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101576","article-title":"Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study","volume":"51","author":"Bruel","year":"2022","journal-title":"EClinicalMedicine"},{"key":"B8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cell.2020.05.025","article-title":"Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells","volume":"182","author":"Cao","year":"2020","journal-title":"Cell"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103904","article-title":"Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong","volume":"77","author":"Peng","year":"2022","journal-title":"EBioMedicine"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abi6950","article-title":"Distinct antibody and memory B cell responses in SARS-CoV-2 na\u00efve and recovered individuals following mRNA vaccination","volume":"6","author":"Goel","year":"2021","journal-title":"Sci Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00404-21","article-title":"Correlates of neutralization against SARS-CoV-2 variants of concern by early pandemic sera","volume":"95","author":"Vidal","year":"2021","journal-title":"J Virol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.1038\/s41467-022-31929-6","article-title":"Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines","volume":"13","author":"Wang","year":"2022","journal-title":"Nat Commun"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29801","article-title":"Neutralization of SARS-CoV-2 Omicron XBB.1.5 and JN.1 variants after COVID-19 booster-vaccination and infection","volume":"96","author":"Springer","year":"2024","journal-title":"J Med Virol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection","volume":"371","author":"Dan","year":"2021","journal-title":"Science"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.121374","article-title":"Functional studies of HLA and its role in SARS-CoV-2: Stimulating T cell response and vaccine development","volume":"318","author":"Lin","year":"2023","journal-title":"Life Sci"},{"key":"B16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s40001-021-00560-4","article-title":"Association of HLA genotypes, AB0 blood type and chemokine receptor 5 mutant CD195 with the clinical course of COVID-19","volume":"26","author":"Fischer","year":"2021","journal-title":"Eur J Med Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/v15040906","article-title":"HLA variation and SARS-CoV-2 specific antibody response","volume":"15","author":"Wolday","year":"2023","journal-title":"Viruses"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00832","article-title":"Human Leukocyte Antigen (HLA) and immune regulation: How do classical and non-classical HLA alleles modulate immune response to human immunodeficiency virus and hepatitis C virus infections","volume":"8","author":"Crux","year":"2017","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101099","article-title":"Increased risk of severe clinical course of COVID-19 in carriers of HLA-C*04:01","volume":"40","author":"Weiner","year":"2021","journal-title":"EClinicalMedicine"},{"key":"B20","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/tan.15160","article-title":"HLA-A*11:01 and HLA-C*04:01 are associated with severe COVID-19","volume":"102","author":"Castro-Santos","year":"2023","journal-title":"HLA"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.641900","article-title":"Association of HLA class I genotypes with severity of coronavirus disease-19","volume":"12","author":"Shkurnikov","year":"2021","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2022.102178","article-title":"HLA variation and antigen presentation in COVID-19 and SARS-CoV-2 infection","volume":"76","author":"Augusto","year":"2022","journal-title":"Curr Opin Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.358","article-title":"Association between HLA gene polymorphisms and mortality of COVID-19: An in silico analysis","volume":"8","author":"Tomita","year":"2020","journal-title":"Immun Inflammation Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.605688","article-title":"Human Leukocyte Antigen complex and other immunogenetic and clinical factors influence susceptibility or protection to SARS-CoV-2 infection and severity of the disease course. The Sardinian experience","volume":"11","author":"Littera","year":"2020","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10101606","article-title":"Knowledge of SARS-CoV-2 epitopes and population HLA types is important in the design of COVID-19 vaccines","volume":"10","author":"Lani","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.709067","article-title":"COVID-19 timeline of Vietnam: Important milestones through four waves of the pandemic and lesson learned","volume":"9","author":"Minh","year":"2021","journal-title":"Front Public Health"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2188\/jea.je20240181","article-title":"An overview strategies and response to the COVID-19 pandemic in Vietnam","volume":"34","author":"Nguyen","year":"2024","journal-title":"J Epidemiol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/bioinformatics\/btz474","article-title":"arcasHLA: high-resolution HLA typing from RNAseq","volume":"36","author":"Orenbuch","year":"2020","journal-title":"Bioinformatics"},{"key":"B29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/infdis\/jiaa673","article-title":"Neutralizing antibody responses in COVID-19 convalescent sera","volume":"223","author":"Lee","year":"2021","journal-title":"J Infect Dis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41577-021-00550-x","article-title":"Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection","volume":"21","author":"Cromer","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2118946","article-title":"Protection and waning of natural and hybrid immunity to SARS-CoV-2","volume":"386","author":"Goldberg","year":"2022","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1126\/science.abg9175","article-title":"mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection","volume":"372","author":"Stamatatos","year":"2021","journal-title":"Science"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.05.063","article-title":"Evidence for antibody as a protective correlate for COVID-19 vaccines","volume":"39","author":"Earle","year":"2021","journal-title":"Vaccine"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04389-z","article-title":"Considerable escape of SARS-CoV-2 Omicron to antibody neutralization","volume":"602","author":"Planas","year":"2022","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2024.110796","article-title":"HLA alleles associated with susceptibility and severity of the COVID-19 in Vietnamese","volume":"85","author":"Hai","year":"2024","journal-title":"Hum Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00784-8","article-title":"Screening HLA-A-restricted T cell epitopes of SARS-CoV-2 and the induction of CD8+ T cell responses in HLA-A transgenic mice","volume":"18","author":"Jin","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.25005","article-title":"The role of HLA genetic variants in COVID-19 susceptibility, severity, and mortality: A global review","volume":"38","author":"Hoseinnezhad","year":"2024","journal-title":"J Clin Lab Anal"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2310917121","article-title":"Antigenic cartography using variant-specific hamster sera reveals substantial antigenic variation among Omicron subvariants","volume":"121","author":"M\u00fchlemann","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1126\/science.abj2258","article-title":"Hybrid immunity","volume":"372","author":"Crotty","year":"2021","journal-title":"Science"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1865246\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:35:48Z","timestamp":1788845748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1865246\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2026.1865246"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1865246","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"article-number":"1865246"}}